C4 Therapeutics, Inc. (CCCC) Stock Price

CCCCStock

$2.77+11.49%52W

Market Cap$340.16M

P/E—

PEG Ratio—

Div yield—

Beta3.17

CCCC Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-9.72%

Price vs S&P 500 (4W)-14.89%

VGM Score48.16

Book Value / Share (Quarterly)$2.01

P/TBV (Annual)0.26x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)4.95%

Cash Flow / Share (Quarterly)$-0.69

Price vs S&P 500 (YTD)32.84%

Net Profit Margin (TTM)-289.44%

EPS (TTM)$-1.00

10-Day Avg Trading Volume2.52M

EPS Excl Extra (TTM)$-1.00

Revenue Growth (5Y)1.60%

EPS (Annual)$-1.27

ROI (Annual)-40.92%

Net Profit Margin (5Y Avg)-364.35%

Cash / Share (Quarterly)$2.06

Revenue Growth QoQ (YoY)2.75%

ROA (Last FY)-29.24%

Revenue Growth TTM (YoY)2.33%

EBITD / Share (TTM)$-0.99

ROE (5Y Avg)-41.87%

Operating Margin (TTM)-318.97%

Cash Flow / Share (Annual)$-1.02

P/B Ratio1.38x

P/B Ratio (Quarterly)2.09x

Net Income / Employee (Annual)$-1,009,600

EV / Revenue (TTM)7.46x

Net Interest Coverage (TTM)-46.66x

ROA (TTM)-30.90%

EPS Incl Extra (Annual)$-1.27

Current Ratio (Annual)7.81x

Quick Ratio (Quarterly)5.29x

3-Month Avg Trading Volume2.78M

52-Week Price Return11.49%

Revenue / Employee (TTM)$336,900

Tangible BV / Share (Quarterly)$4.39

P/S Ratio (Annual)9.46x

Asset Turnover (Annual)0.10x

52-Week High$5.17

Operating Margin (5Y Avg)-385.07%

EPS Excl Extra (Annual)$-1.27

CapEx CAGR (5Y)-1.36%

26-Week Price Return0.18%

Quick Ratio (Annual)7.60x

13-Week Price Return-25.07%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)5.45x

Enterprise Value$261.55M

Revenue / Share Growth (5Y)-10.87%

Asset Turnover (TTM)0.11x

Book Value / Share Growth (5Y)-16.48%

Revenue / Employee (Annual)$345,600

Pretax Margin (Annual)-291.74%

Cash / Share (Annual)$2.56

3-Month Return Std Dev62.42%

Net Income / Employee (TTM)$-975,200

ROE (Last FY)-40.92%

Net Interest Coverage (Annual)-88.52x

EPS Basic Excl Extra (Annual)$-1.27

Receivables Turnover (TTM)20.07x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.00

Receivables Turnover (Annual)13.06x

ROI (TTM)-45.45%

P/S Ratio (TTM)9.71x

Pretax Margin (5Y Avg)-362.97%

Revenue / Share (Annual)$0.43

Tangible BV / Share (Annual)$5.91

Price vs S&P 500 (52W)-4.04%

Year-to-Date Return44.76%

5-Day Price Return-9.64%

EPS Normalized (Annual)$-1.27

ROA (5Y Avg)-28.17%

Net Profit Margin (Annual)-292.08%

Month-to-Date Return-16.97%

Cash Flow / Share (TTM)$-2.71

EBITD / Share (Annual)$-1.37

Operating Margin (Annual)-320.53%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-41.42%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.00

P/TBV (Quarterly)0.35x

P/B Ratio (Annual)0.72x

Pretax Margin (TTM)-289.09%

Book Value / Share (Annual)$2.65

Price vs S&P 500 (13W)-27.75%

Beta3.17x

P/FCF (Annual)6.27x

Revenue / Share (TTM)$0.27

ROE (TTM)-45.45%

52-Week Low$1.69

vGradeC

gGradeC

mGradeC

vgmGradeC

CCCC Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 11, 2026	-$0.23	-$0.18	+21.74%(+$0.05)
Q1 2026	May 12, 2026	-$0.26	-$0.20	+23.08%(+$0.06)
Q4 2025	Feb 26, 2026	-$0.39	-$0.18	+54.24%(+$0.21)
Q3 2025	Nov 6, 2025	-$0.39	-$0.30	+24.64%(+$0.10)
Q2 2025	Aug 7, 2025	-$0.38	-$0.37	+3.27%(+$0.01)

CCCC Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.29

4.23

Industry Peers — Biological Products(186)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
CCCCC4 Therapeutics, Inc.	C	C	C	9.7x	2.3%	—	—	$2.77
AMGNAmgen Inc	D	C	A	6.1x	9.1%	74.3%	2.9%	$432.49
GILDGilead Sciences Inc	C	B	A	6.4x	5.5%	79.6%	133.6%	$156.19
MRNAModerna, Inc. Common Stock	F	C	A	39.1x	-27.6%	36.4%	—	$218.01
ARGXargenx SE American Depositary Shares	D	A	B	6.6x	165.2%	89.8%	—	$819.14
RVMDRevolution Medicines, Inc. Common Stock	F	—	B	3296.2x	—	—	—	$177.96
BIIBBiogen Inc. Common Stock	C	D	A	3.4x	0.3%	74.0%	-18.8%	$232.65
BNTXBioNTech SE American Depositary Share	C	C	C	7.6x	-11.8%	79.2%	—	$87.71
EXELExelixis Inc	C	B	A	6.3x	9.2%	96.5%	31.1%	$62.23
HALOHalozyme Therapeutics, Inc.	D	B	A	8.3x	41.1%	82.4%	22.9%	$121.84
NBIXNeurocrine Biosciences Inc	C	B	B	4.1x	34.4%	98.0%	2.3%	$135.71
TECHBio-Techne Corp.	D	C	B	9.4x	-0.4%	66.2%	6.0%	$72.57
RGENRepligen Corp	F	C	A	14.2x	16.5%	53.8%	-4.9%	$175.42
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	—	—	—	—	$135.07
PCVXVaxcyte, Inc. Common Stock	—	—	B	—	—	—	—	$63.62
IBRXImmunityBio, Inc. Common Stock	F	A	A	58.7x	192.9%	99.3%	—	$9.18
QGENQIAGEN N.V.	C	C	B	4.5x	3.0%	62.5%	4.2%	$46.13
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	21.3x	22.6%	94.6%	—	$316.58
TWSTTwist Bioscience Corporation Common Stock	D	B	A	20.2x	19.2%	52.0%	—	$132.75
KYMRKymera Therapeutics, Inc. Common Stock	F	B	B	83.0x	134.8%	—	—	$104.78
IOVAIovance Biotherapeutics, Inc. Common Stock	D	B	A	19.0x	34.5%	48.4%	—	$13.62
IMVTImmunovant, Inc. Common Stock	—	—	C	—	—	—	—	$26.73
KODKodiak Sciences Inc Common Stock	—	—	A	—	—	—	—	$85.75
CGONCG Oncology, Inc. Common stock	F	A	B	851.8x	1030.3%	-85.2%	—	$59.85
SRRKScholar Rock Holding Corporation Common Stock	F	—	C	102.7x	—	—	—	$39.90
CRSPCRISPR Therapeutics AG	D	B	B	355.6x	-64.8%	—	—	$49.25
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	B	12.4x	50.1%	75.6%	—	$24.02
RLAYRelay Therapeutics, Inc. Common Stock	F	D	B	344.7x	23.9%	—	—	$16.28
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	5.5x	105.2%	93.3%	—	$68.07
DNLIDenali Therapeutics Inc. Common Stock	F	—	C	781.1x	—	—	—	$17.61
BEAMBeam Therapeutics Inc. Common Stock	D	B	C	15.5x	158.9%	—	—	$23.47
ADMAADMA Biologics, Inc.	C	C	B	4.7x	8.0%	64.7%	—	$10.68
VCELVericel Corporation	D	B	B	6.7x	22.9%	74.6%	38.9%	$40.13
BCRXBioCryst Pharmaceuticals Inc	B	A	B	2.1x	68.7%	97.8%	—	$7.79
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	33.9x	-15.1%	3.5%	—	$3.46
NVAXNovavax Inc	C	D	B	4.5x	-61.6%	79.2%	—	$11.26
ALVOAlvotech Ordinary Shares	D	D	B	3.9x	-12.1%	60.7%	—	$5.00
MESOMesoblast Limited American Depositary Shares	D	A	C	14.6x	599.2%	86.1%	—	$13.28
VIRVir Biotechnology, Inc. Common Stock	B	B	B	5.6x	1496.1%	100.0%	—	$9.96
MAZEMaze Therapeutics, Inc. Common Stock	—	A	B	—	700.0%	—	—	$27.53
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	3.5x	20.9%	98.9%	—	$29.40
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	C	—	—	—	—	$30.07
INBXInhibrx Biosciences, Inc. Common Stock	D	C	A	944.3x	550.0%	—	—	$89.83
TSHATaysha Gene Therapies, Inc. Common Stock	D	C	D	120.7x	-32.3%	—	—	$3.62
IMTXImmatics N.V. Ordinary Shares	C	C	C	21.5x	-68.0%	—	—	$6.73
REPLReplimune Group, Inc.	—	—	B	—	—	—	—	$10.86
VORVor Biopharma Inc. Common Stock	—	—	C	—	—	—	—	$18.03
MGTXMeiraGTx Holdings plc Ordinary Shares	C	A	C	2.2x	948.4%	98.0%	—	$9.28
SLBTSL Science Holding Limited Ordinary Shares	—	—	D	—	—	—	—	$1.53
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	C	—	—	—	—	$12.93
GLUEMonte Rosa Therapeutics, Inc. Common Stock	D	F	D	28.9x	-83.9%	—	—	$9.74

About C4 Therapeutics, Inc.

C4 Therapeutics is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies designed to address difficult-to-treat cancers and other diseases. Its proprietary TORPEDO platform enables the efficient design of small-molecule degraders that leverage the body's natural protein recycling system to overcome drug resistance and tackle undruggable targets. The company's pipeline includes three oncology programs: Cemsidomide, CFT1946, and CFT8919.